The Biden-Harris Administration announced on April 4 that more than 59 million Americans with Medicare Part B, including those enrolled in a Medicare Advantage plan, now have access to Food and Drug Administration (FDA) approved, authorized, or cleared OTC COVID-19 tests at no cost.
Agilent Technologies on Tuesday announced it has obtained expanded CE-IVD marking for the use of its PD-L1 IHC 28-8 pharmDx immunohistochemical assay as a companion diagnostic test to guide treatment for newly approved indications for Bristol Myers Squibb's Opdivo.
Foundation Medicine said on Thursday that the US Food and Drug Administration has approved its FoundationOne CDx test as a companion diagnostic to identify non-small cell lung cancer patients with EGFR exon 19 deletions or exon 21 alterations for treatment with EGFR inhibitors.
Burning Rock Biotech said on Tuesday that the National Medical Products Administration of China has approved its nine-gene sequencing assay, LungCure CDx, as a Class III medical device.
The development of new scientific ways to see more deeply into the building blocks of nature on a cellular level has led to the some of the greatest advances in medicine over the last century.
Recently, the domestic epidemic situation is severe, and the release of the "Plan" further optimizes the COVID-19 detection strategy to serve the needs of epidemic prevention and control.
Cancer detection is a major public health challenge, and the methods currently available to achieve it, for example MRIs and mammograms, are often expensive and invasive.
Canadian firm MedMira said Wednesday it has obtained the CE mark for its Reveal TP (Syphilis) test, making it available in the European Union as well as other geographies that accept the designation.
A review of adverse events following vaccination against COVID-19 with mRNA vaccines in the USA confirms that most side effects were mild and decreased substantially after one day.
One of the most promising avenues in treating cancer is to restore our immune system’s ability to recognize and attack cancerous cells.
✔ All (73)
✔ Press release (0)
✔ Industry news (73)
Don’t miss important updates about the show and the in vitro diagnostic industry.
Sign-up for our newsletter today.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.